Welcome to our dedicated page for Aethlon Medical SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Aethlon Medical’s SEC paperwork can feel harder than understanding its Hemopurifier science. Pages of R&D expense tables, FDA correspondence, and dilution math often bury the details investors need. Stock Titan’s AI turns that maze into a clear map.
Search “Aethlon Medical annual report 10-K simplified” or “Aethlon Medical quarterly earnings report 10-Q filing” and arrive here first. Our platform ingests every 8-K, 10-Q, 10-K, S-1, and Aethlon Medical insider trading Form 4 transactions the moment they hit EDGAR. Then AI highlights the burn rate behind Hemopurifier trials, flags new biodefense grants, and explains why an 8-K mentions protocol amendments—so you understand Aethlon Medical 8-K material events explained without legalese.
Need rapid insight? Toggle real-time alerts for Aethlon Medical Form 4 insider transactions real-time to see when executives buy shares during pivotal oncology data releases. Compare segments with our visual summaries inside each “Aethlon Medical earnings report filing analysis”. Drill into the proxy to examine Aethlon Medical proxy statement executive compensation, or ask natural questions like “understanding Aethlon Medical SEC documents with AI” and get concise answers. Whether you track Aethlon Medical executive stock transactions Form 4 before financing rounds or gauge trial milestones hidden in MD&A, our coverage keeps you ahead—no PhD in regulatory jargon required.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 185,000 shares of Aethlon Medical Inc. Together they hold 7.16% of the outstanding common stock, based on 2,585,316 shares outstanding as of June 24, 2025. Armistice Capital is the investment manager of the Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over the securities. Mr. Boyd, as managing member, is reported to share those voting and disposition rights. The Master Fund disclaims direct beneficial ownership due to its investment management agreement.
Aethlon Medical, Inc. (AEMD) reported a quarterly net loss of $1.76 million for the three months ended June 30, 2025, an improvement from $2.57 million a year earlier driven by lower payroll and professional fees. Revenue remained $0; operating expenses declined to $1.79 million from $2.62 million as headcount-related costs, severance and certain consulting fees decreased. Basic and diluted loss per share was ($0.85) versus ($2.76) in the prior year on a larger weighted-average share base of 2,076,416 shares.
Balance sheet highlights: cash and cash equivalents were $3.77 million, total assets $5.31 million, total liabilities $1.88 million, and stockholders' equity $3.42 million. Working capital fell to $2.42 million from $4.05 million at March 31, 2025. Management discloses substantial doubt about the company's ability to continue as a going concern and expects existing cash to be insufficient to fund operations for at least twelve months without additional financing.
Clinical and operational updates stated explicitly: the Hemopurifier phase 1 oncology trial is active at three Australian sites, three participants were treated in cohort 1 with no DSMB safety concerns, cohort 2 enrollment is open, the planned India trial (CDSCO-approved July 7, 2025) was cancelled to conserve resources, and a preprint reported >98% removal of platelet-derived EVs in an ex-vivo study. The company effected a 1-for-8 reverse stock split effective June 9, 2025 and maintains an open IDE for viral indications.
Aethlon Medical (Nasdaq:AEMD) filed a Form 8-K to furnish its press release announcing financial results for the quarter ended March 31, 2025. Reported under Items 2.02 and 7.01, the filing attaches the release as Exhibit 99.1 and states the information is provided under Regulation FD and not deemed “filed” for Exchange Act purposes. No detailed financial metrics, guidance, or strategic updates are included in the 8-K itself. Aside from furnishing the exhibit, the report discloses no material events likely to affect the company’s operating outlook or capital structure. Investors must review Exhibit 99.1 for the actual results.
Aethlon Medical (NASDAQ:AEMD) filed its Annual Report for the fiscal year ended March 31, 2025.
- Maintains status as a non-accelerated filer & smaller reporting company.
- Implemented a 1-for-8 reverse stock split effective June 6 2025; post-split shares outstanding total 2,585,316.
- Aggregate market value of non-affiliate shares was $6.65 million as of Sept 30 2024 (close $3.73).
- Discloses May 2024 public offering and March 2025 warrant inducement; details appear in Equity & Liquidity sections.
- No indication of being a shell company or well-known seasoned issuer; all Exchange Act filings current.
The filing provides audited FY 2025 financial statements, updated risk factors, new Cybersecurity disclosures and forward-looking statements that may affect future capital raising and regulatory pathways.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
